Bessemer Group’s Kyntra Bio KYNB Stock Holding History

Bessemer Group’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4	Closed	-$1K	–	1914
2022 Q1	$1K	Hold	4	–	–	﹤0.01%	1771
2021 Q4	$1K	Hold	4	–	–	﹤0.01%	1806
2021 Q3	$1K	Hold	4	–	–	﹤0.01%	1625
2021 Q2	$3K	Hold	4	–	–	﹤0.01%	1471
2021 Q1	$3K	Buy	+4	New	+$4.26K	﹤0.01%	1429
2016 Q1	–	Sell	-3	Closed	-$2K	–	1537
2015 Q4	$2K	Buy	+3	New	+$1.99K	﹤0.01%	1498

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bessemer Group's KYNB Position: Q2 2022 in Review

Bessemer Group sold out of Kyntra Bio (KYNB) in Q2 2022, closing a stake of 4 shares — an estimated $1K sold.

Bessemer Group first reported a position in KYNB in Q4 2015 and held it in 6 quarters. The position peaked at $3K in Q2 2021. 150 funds tracked by Wall St. Rank hold KYNB as of Q2 2022.

Bessemer Group reported no remaining Kyntra Bio position as of Q2 2022 after selling out during the quarter.
Bessemer Group sold 4 Kyntra Bio shares in Q2 2022, an estimated $1K.
Bessemer Group first reported a position in Kyntra Bio in Q4 2015 and held it in 6 quarters.
Bessemer Group's Kyntra Bio position peaked at $3K in Q2 2021.
150 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2022.

Based on Bessemer Group's 13F filing for Q2 2022, filed 10 Aug 2022.